Role of Activin A in human cancer cachexia
(2021)
Files
ThèseAudreyLoumayefinalPDF.pdf
Restricted Access - Adobe PDF
- 4 MB
Details
- Authors
- Supervisors
- Thissen, Jean-Paul
- Abstract
- The skeletal muscle wasting, occurring during cancer cachexia (CC), is a factor of poor prognosis. In animals, maintaining muscle mass prolongs survival, regardless of the tumor evolution. Preserving muscle mass appears therefore as a major therapeutic goal in oncology. Preclinical works indicate that Activin A (ActA) contributes to the development of skeletal muscle atrophy during CC. Our aim is to investigate the role of ActA in human CC. We show that high levels of circulating ActA are associated with cachexia and poor survival in cancer patients. In addition, ActA induces atrophy of human muscle cells by inhibiting myogenesis. ActA negatively regulates MRFs and MEF2C and consequently alters Myosin heavy chain-β/slow synthesis. This study highlights ActA as a marker but also a potential player in CC development in humans. Moreover, we identify a novel interaction between ActA/pSmad2/3 signaling and MEF2C transcriptional activity.
- Affiliations
Citations
Loumaye, A. (2021). Role of Activin A in human cancer cachexia. https://hdl.handle.net/2078.5/112547